ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0686

Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

(0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes

9:00AM-11:00AM: Abstract Number: 0268

Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0219

Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0217

Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0209

Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0361

Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0631

Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0444

Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: PP10

Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 0621

Scleroderma Renal Crisis: A Large Single-center Experience

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0601

Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0461

Self-esteem as a Determinant of Sexual Function in SLE Patients

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0327

Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0150

Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies

(0145–0154) Epidemiology & Public Health – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 0614

Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].